CytoDyn Inc. (CYDY) stock
CYDYOTCPharmaceutical PreparationsFiscal year ends May 31
$0.25+0.02 (+9.53%)
Close on Oct 19, 2026Market cap $345.56MP/E –Yield –
CytoDyn r&d expenses
Research and development expenses are spending on new products and technology.
CytoDyn's R&D Expenses for the twelve months ending May 31, 2024 was $7.24M. For fiscal 2024 it was $7.24M, up 175.1% from the year before. Over ten years it grew 6.2% a year on average. The highest annual figure on record is $53.40M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | May 31, 2024 | $7.24M | +175.1% |
| FY2023 | May 31, 2023 | $2.63M | -90.3% |
| FY2022 | May 31, 2022 | $27.04M | -49.4% |
| FY2021 | May 31, 2021 | $53.40M | +1.4% |
| FY2020 | May 31, 2020 | $52.64M | +23.9% |
| FY2019 | May 31, 2019 | $42.49M | +11.2% |
| FY2018 | May 31, 2018 | $38.22M | +89.2% |
| FY2017 | May 31, 2017 | $20.21M | +47.1% |
| FY2016 | May 31, 2016 | $13.73M | -9.4% |
| FY2015 | May 31, 2015 | $15.16M | +280.7% |
| FY2014 | May 31, 2014 | $3.98M | +542.3% |
| FY2013 | May 31, 2013 | $619.84K | +16.9% |
| FY2012 | May 31, 2012 | $530.03K | +10.2% |
| FY2011 | May 31, 2011 | $480.77K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024CQ2 2024 | May 31, 2024 | $3.60M | +2525.5% |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | $650.00K | +12.8% |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | $1.08M | -73.1% |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | $1.91M | -46.4% |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | $137.00K | -98.2% |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | $576.00K | -95.2% |
| Q4 FY2022CQ2 2022 | May 31, 2022 | $4.01M | -57.1% |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | $3.57M | -71.0% |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | $7.45M | -54.7% |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | $12.02M | -20.9% |
| Q4 FY2021CQ2 2021 | May 31, 2021 | $9.34M | -53.2% |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | $12.32M | -18.4% |
| Q2 FY2021CQ4 2020 | Nov 30, 2020 | $16.45M | +92.9% |
| Q1 FY2021CQ3 2020 | Aug 31, 2020 | $15.19M | +67.7% |
| Q4 FY2020CQ2 2020 | May 31, 2020 | $19.95M | +116.9% |
| Q3 FY2020CQ1 2020 | Feb 29, 2020 | $15.11M | +67.5% |
| Q2 FY2020CQ4 2019 | Nov 30, 2019 | $8.53M | -33.7% |
| Q1 FY2020CQ3 2019 | Aug 31, 2019 | $9.06M | -20.6% |
| Q4 FY2019CQ2 2019 | May 31, 2019 | $9.20M | +3.1% |
| Q3 FY2019CQ1 2019 | Feb 28, 2019 | $9.02M | -25.3% |
| Q2 FY2019CQ4 2018 | Nov 30, 2018 | $12.87M | +41.8% |
| Q1 FY2019CQ3 2018 | Aug 31, 2018 | $11.40M | +39.9% |
| Q4 FY2018CQ2 2018 | May 31, 2018 | $8.92M | +59.2% |
| Q3 FY2018CQ1 2018 | Feb 28, 2018 | $12.08M | +84.8% |
| Q2 FY2018CQ4 2017 | Nov 30, 2017 | $9.08M | +107.1% |
| Q1 FY2018CQ3 2017 | Aug 31, 2017 | $8.15M | +121.1% |
| Q4 FY2017CQ2 2017 | May 31, 2017 | $5.60M | – |
| Q3 FY2017CQ1 2017 | Feb 28, 2017 | $6.53M | – |
| Q2 FY2017CQ4 2016 | Nov 30, 2016 | $4.38M | – |
| Q1 FY2017CQ3 2016 | Aug 31, 2016 | $3.69M | – |
See a number that looks wrong?